Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
NCT03688178Phase 2Active, not recruiting
- Sponsor
- Istari Oncology
- Start
- Aug 2020
- Primary completion
- Mar 2027
- Modality
- Whole Cell Cancer Vaccines, Recombinant Proteins and Enzymes, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of varlilumab, tetanus and diphtheria toxoids adsorbed, CMV pp65-LAMP mRNA-pulsed autologous dendritic cells in glioblastoma (GBM), sponsored by Istari Oncology. Started Aug 2020; status: active, not recruiting.
02
Drugs
varlilumabtetanus and diphtheria toxoids adsorbedCMV pp65-LAMP mRNA-pulsed autologous dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03688178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688178.